Stockreport

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patient [Read more]